Takeda Pharmaceutical Company Limited (TYO:4502)
Japan · Delayed Price · Currency is JPY 4,366.00
+9.00 (0.21%)
Aug 14, 2025, 3:30 PM JST
Revenue by Product
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2013 - 2020 |
Gastroenterology Revenue (Pre-FY2023 Reporting) | - | Log In | Log In | Log In | Log In | Upgrade |
Gastroenterology Revenue (Pre-FY2023 Reporting) Growth | - | Log In | Log In | Log In | Log In | Upgrade |
PDT Immunology Revenue (Pre-FY2023 Reporting) | - | Log In | Log In | Log In | Log In | Upgrade |
PDT Immunology Revenue (Pre-FY2023 Reporting) Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Oncology Revenue (Pre-FY2023 Reporting) | - | Log In | Log In | Log In | Log In | Upgrade |
Oncology Revenue (Pre-FY2023 Reporting) Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Neuroscience Revenue (Pre-FY2023 Reporting) | - | Log In | Log In | Log In | Log In | Upgrade |
Neuroscience Revenue (Pre-FY2023 Reporting) Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other Product Revenue (Pre-FY2023 Reporting) | - | Log In | Log In | Log In | Log In | Upgrade |
Other Product Revenue (Pre-FY2023 Reporting) Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Rare Metabolic | - | Log In | Log In | Log In | Log In | Upgrade |
Rare Metabolic Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Rare Hematology | - | Log In | Log In | Log In | Log In | Upgrade |
Rare Hematology Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Hereditary Angioedema | - | Log In | Log In | Log In | Log In | Upgrade |
Hereditary Angioedema Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Total Rare Diseases Revenue (Pre-FY2023 Reporting) | - | Log In | Log In | Log In | Log In | Upgrade |
Total Rare Diseases Revenue (Pre-FY2023 Reporting) Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other Rare Disease | - | Log In | Log In | Log In | Log In | Upgrade |
Other | 1.00M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | -127.71% | Log In | Log In | Log In | Log In | Upgrade |
GI Revenue (Post-FY2024 Reporting) | 1,357.02B | Log In | Log In | Log In | Log In | Upgrade |
GI Revenue (Post-FY2024 Reporting) Growth | 6.03% | Log In | Log In | Log In | Log In | Upgrade |
Rare Diseases Revenue (Post-FY2024 Reporting) | 752.82B | Log In | Log In | Log In | Log In | Upgrade |
Rare Diseases Revenue (Post-FY2024 Reporting) Growth | 4.55% | Log In | Log In | Log In | Log In | Upgrade |
PDT Revenue (Post-FY2024 Reporting) | 1,032.66B | Log In | Log In | Log In | Log In | Upgrade |
PDT Revenue (Post-FY2024 Reporting) Growth | 5.83% | Log In | Log In | Log In | Log In | Upgrade |
Oncology Revenue (Post-FY2024 Reporting) | 560.43B | Log In | Log In | Log In | Log In | Upgrade |
Oncology Revenue (Post-FY2024 Reporting) Growth | 12.77% | Log In | Log In | Log In | Log In | Upgrade |
Vaccines | 55.41B | Log In | Log In | Log In | Log In | Upgrade |
Vaccines Growth | 3.82% | Log In | Log In | Log In | Log In | Upgrade |
Neuroscience Revenue (Post-FY2024 Reporting) | 565.82B | Log In | Log In | Log In | Log In | Upgrade |
Neuroscience Revenue (Post-FY2024 Reporting) Growth | -18.38% | Log In | Log In | Log In | Log In | Upgrade |
Other Product Revenue (Post-FY2024 Reporting) | 257.39B | Log In | Log In | Log In | Log In | Upgrade |
Other Product Revenue (Post-FY2024 Reporting) Growth | -17.00% | Log In | Log In | Log In | Log In | Upgrade |
Other | 1.00M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | -127.71% | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2013 - 2020 |
Other | - | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 10.92% | Log In | Log In | Log In | Log In | Upgrade |
Japan | 418.46B | Log In | Log In | Log In | Log In | Upgrade |
Japan Growth | -1.37% | Log In | Log In | Log In | Log In | Upgrade |
United States | 2,379.65B | Log In | Log In | Log In | Log In | Upgrade |
United States Growth | 0.51% | Log In | Log In | Log In | Log In | Upgrade |
Europe and Canada | 1,055.25B | Log In | Log In | Log In | Log In | Upgrade |
Europe and Canada Growth | 3.51% | Log In | Log In | Log In | Log In | Upgrade |
Latin America | 235.85B | Log In | Log In | Log In | Log In | Upgrade |
Latin America Growth | -2.38% | Log In | Log In | Log In | Log In | Upgrade |
Russia / CIS | 72.36B | Log In | Log In | Log In | Log In | Upgrade |
Russia / CIS Growth | -1.69% | Log In | Log In | Log In | Log In | Upgrade |
Other Geographic | 128.85B | Log In | Log In | Log In | Log In | Upgrade |
Other Geographic Growth | 2.95% | Log In | Log In | Log In | Log In | Upgrade |
China | 191.74B | Log In | Log In | Log In | Log In | Upgrade |
China Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Asia (ex-Japan & China) | 99.39B | Log In | Log In | Log In | Log In | Upgrade |
Asia (ex-Japan & China) Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | - | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 10.92% | Log In | Log In | Log In | Log In | Upgrade |